Technical Analysis for ALKS - Alkermes plc

Grade Last Price % Change Price Change
grade C 21.0 5.37% 1.07
ALKS closed up 5.37 percent on Friday, November 15, 2019, on 1.92 times normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Up Up
See historical ALKS trend table...

Date Alert Name Type % Chg
Expansion Pivot Buy Setup Bullish Swing Setup 0.00%
Pocket Pivot Bullish Swing Setup 0.00%
Multiple of Ten Bullish Other 0.00%
Above Upper BB Strength 0.00%
Upper Bollinger Band Touch Strength 0.00%
Crossed Above 20 DMA Bullish 5.37%
Crossed Above 50 DMA Bullish 5.37%
180 Bullish Setup Bullish Swing Setup 5.37%
Fell Below 20 DMA Bearish 8.30%
Fell Below 50 DMA Bearish 8.30%

Older signals for ALKS ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Alkermes Public Limited Company, an integrated biopharmaceutical company, develops medicines that enhance patient outcomes. The company offers RISPERDAL CONSTA for schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia; AMPYRA/ FAMPYRA for the treatment of multiple sclerosis; BYDUREON for the treatment of type II diabetes; VIVITROL for alcohol and opioid dependence; TRICOR, LIPANTHYL, LIPIDIL, and SUPRALIP to lower cholesterol; ZANAFLEX for muscle spasticity; AVINZA for severe pain; EMEND for the treatment of nausea associated with chemotherapy and surgery; and FOCALIN XR and RITALIN LA for attention deficit and hyperactivity disorder. Its products also include MEGACE ES for the treatment of cachexia associated with AIDS; LUVOX CR for obsessive-compulsive disorder; RAPAMUNE for the prevention of renal transplant rejection; NAPRELAN for various mild to moderate pain indications; VERAPAMIL SR, VERELAN, VERELAN PM, VERAPAMIL PM, VERECAPS, UNIVER, and AFE Ditab CR for hypertension; and DILZEM SR, DILZEM XL, DILTELAN, ACALIX CD, DINISOR, TILAZEM CR, and CARDIZEM CD for hypertension and/or angina. In addition, it develops ALKS 9070, which is in phase 3 study for the treatment of schizophrenia; ALKS 37 that is under phase 2b study for the treatment of opioid-induced constipation; ALKS 33, which has completed phase 2 study for modulation of brain opioid receptors; ALKS 5461 that is under phase 2 study for the treatment of depressive disorder, as well as under phase 1b study for the treatment of cocaine dependence; and ZOHYDRO for pain relief. The company serves pharmaceutical wholesalers, specialty pharmacies, and specialty distributors directly through its sales force. It has collaboration with Janssen Pharmaceutica N.V. for the development of RISPERDAL CONSTA. The company was founded in 1987 and is headquartered in Dublin, Ireland.
Chemistry Biopharmaceutical Pain Surgery Chemotherapy Multiple Sclerosis Schizophrenia Organic Chemistry Hypertension Morphinans Neurochemistry Nausea Ii Diabetes Obsessive Compulsive Disorder Angina Depressive Disorder Opioid Antagonists Pharmaceutical Wholesalers Treatment Of Multiple Sclerosis AIDS Atypical Antipsychotics Opioid Induced Constipation Renal Transplant
Is ALKS a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 1 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 37.75
52 Week Low 17.11
Average Volume 1,343,784
200-Day Moving Average 25.3581
50-Day Moving Average 19.7451
20-Day Moving Average 19.6588
10-Day Moving Average 19.993
Average True Range 0.831
ADX 17.89
+DI 26.8323
-DI 17.9928
Chandelier Exit (Long, 3 ATRs ) 18.527
Chandelier Exit (Short, 3 ATRs ) 20.103
Upper Bollinger Band 20.8534
Lower Bollinger Band 18.4642
Percent B (%b) 1.06
BandWidth 12.153336
MACD Line 0.243
MACD Signal Line 0.1326
MACD Histogram 0.1104
Fundamentals Value
Market Cap 3.23 Billion
Num Shares 154 Million
EPS -1.29
Price-to-Earnings (P/E) Ratio -16.28
Price-to-Sales 10.50
Price-to-Book 7.03
PEG Ratio -1145.21
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 22.70
Resistance 3 (R3) 22.51 21.77 22.41
Resistance 2 (R2) 21.77 21.34 21.86 22.32
Resistance 1 (R1) 21.38 21.07 21.58 21.57 22.22
Pivot Point 20.64 20.64 20.73 20.73 20.64
Support 1 (S1) 20.25 20.21 20.45 20.44 19.78
Support 2 (S2) 19.51 19.94 19.60 19.68
Support 3 (S3) 19.12 19.51 19.59
Support 4 (S4) 19.31